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MACE was the abbreviation of “major adverse cardiovascular
events.” In Table 4 and the related results part, MACE referred
to “major adverse coronary events.” Furthermore, “major ad-
verse cardiac events” appeared in the abstract and result part as
another full name of MACE. According to the recommenda-
tion of the Academic Research Consortium (2), the term
MACE can be device-oriented or patient-oriented. Without
any definition and identical full name of MACE in the
SESAMI trial, a formidable barrier was built to understanding
the results and to comparison with other clinical trials.
My other concern is the inclusion criteria of the patients. In the
Menichelli article (1), all the patients had AMI eligible for primary
angioplasty, which seemed to be confirmed later in the catheter-
ization and study procedure part. But in the slides presented by the
author in EuroPCR 2006 (3), the rate of rescue coronary angio-
plasty accounted for 17.5% in the sirolimus-eluting stent (SES)
group and 17.7% in the BMS group. The related information on
rescue percutaneous coronary intervention in the study design and
protocol should be described because it was a different treatment
strategy for AMI patients.
By the way, the value of standard deviation of stent diameter in
the SES group in Table 2 might be 0.34 instead of 0.034,
according to the context.
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Reply
We appreciate the effort made by Dr. Pan in emphasizing the need
for consistent end points in the medical literature. He refers to the
“formidable barrier” reported by Dr. Cutlip (1) in understanding
results across clinical trials. We agree that consistency across
well-considered end point definitions is critical.
In our trial (2), we used a device-oriented composite definition
of major adverse cardiac events (MACE). However, as Dr. Cutlip
reported, “composite acronyms such as MACE have been used so
frequently with so many variations in definition that the ARC
recommends that the term be avoided altogether.”
In designing the SESAMI (Sirolimus-Eluting Stent Versus
Bare-Metal Stent in Acute Myocardial Infarction) trial, we tried to
establish consistency among end point definitions. Indeed, this
trial was among the first to adopt and utilize the new Academic
Research Consortium definition of stent thrombosis—well before
Dr. Cutlip’s article was published.
As far as inclusion criteria are concerned, all of the patients
presented with ST-elevation myocardial infarction and were
eligible for primary angioplasty. We adopted the same strategy
for all the patients once they were in our catheterization
laboratory; however, a small portion of them had previously
received thrombolytic therapy, as reported in Table 1 of our
original study (2).
Dr. Pan surmises correctly that decimal point was mis-
placed in the standard deviation value for the sirolimus-eluting
stent diameter in Table 2 of our study (2). The correct value is
0.034.
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Resting Heart Rate and
Cardiovascular Disease: The
Beta-Blocker–Hypertension Paradox
The hypothesis of Fox et al. (1) of heart rate being an independent
predictor of cardiovascular and all-cause mortality in people with
and without diagnosed cardiovascular disease is convincing and
supported by a solid body of evidence. Considerably less well
documented is that pharmacologic heart rate slowing within the
physiologic range will reduce cardiovascular events or, indeed,
increase longevity. As Fox et al. (1) point out, it is likely that the
beneficial effect of beta-blockers after myocardial infarction and in
congestive heart failure is, at least to some extent, related to a
reduction in heart rate. However, the opposite seems to be true in
hypertension: we recently found a greater risk of cardiovascular
events (all-cause mortality, cardiovascular mortality, myocardial
infarction, stroke, and heart failure, all p  0.0001) with a lower
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heart rate in a meta-analysis of more than 60,000 patients in 9
large beta-blocker trials (2). Thus, the greater the heart rate
reduction with beta-blockers, the greater the risk of cardiovascular
events in hypertensive patients. The reason that drug-induced
bradycardia is less beneficial than spontaneously occurring brady-
cardia may be related to the dyssynchrony of the reflected pulse
wave and the outgoing pressure wave. Ideally, the reflected wave
should return toward the heart during diastole to augment diastolic
filling. If the wave returns earlier during the cardiac cycle, as is the
case with pharmacologic heart rate slowing, it amplifies the
outgoing pressure wave, thereby increasing systolic pressure. In-
deed, findings from the CAFÉ (Conduit Artery Function Evalu-
ation) (3) study, in which pulse-wave analysis was used to derive
central aortic pressure, documented a pseudo-antihypertensive
effect of the beta-blocker regimen (4). Despite identical brachial
pressure in both treatment arms, central aortic systolic pressure was
lowered significantly less well with atenolol than with amlodipine.
Thus, pulse-wave dyssynchrony, secondary to heart rate slowing,
may account for the beta-blocker–hypertension paradox. This
would indicate that not all heart rate slowing is created equal—
bradycardia induced by negative chronotropic drugs may not
necessarily be as beneficial as bradycardia occurring spontaneously
or being related to aerobic conditioning.
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Reply
Resting heart rate is a strong predictor of cardiovascular and
all-cause mortality in various populations, including hypertensive
patients. Moreover, the strong relationship between heart rate
reduction and mortality reduction has been robustly established by
data on the effect of beta-blockers and, to a lesser extent, heart
rate-reducing calcium-channel blockers in patients after myocar-
dial infarction (MI) and with heart failure (HF) (1).
In their letter to the Journal, Drs. Messerli and Bangalore
suggest that bradycardia induced by negative chronotropic drugs
may not necessarily be as beneficial as bradycardia occurring
physiologically and support the suggestion with the observation
that blood pressure reduction with beta-blockers, which is associ-
ated with heart rate reduction, is less beneficial in minimizing
cardiovascular outcome in hypertensive patients as compared with
other non-heart rate slowing antihypertensive agents.
In contrast with post-MI or HF studies, the beta-blocker
atenolol was the chronotropic drug used in most of the hyperten-
sion clinical trials reported by Drs. Messerli and Bangalore. By
reducing heart rate and myocardial inotropism and increasing left
ventricular (LV) ejection time, atenolol (like the majority of
beta-blockers) alters the pattern of pulse-wave reflection. The
increase in the augmentation index reported after beta-blockers
results in increased central systolic blood pressure in hypertensive
patients. Thus, beta-blockers could have a deleterious effect on
LV-aortic coupling, LV afterload, LV hypertrophy, and, ulti-
mately, the risk of cardiovascular events. The observations could
explain the less-than-expected beneficial effect of atenolol on
clinical outcome in the CAFÉ (Conduit Artery Function Evalu-
ation) study (2) reported by Drs. Messerli and Bangalore.
However, although the pulse-wave dyssynchrony observed with
atenolol may account for the beta-blocker paradox and the increase
in central blood pressure observed in hypertensive patients, we
should be cautious about attributing the phenomenon to heart rate
slowing per se. As previously mentioned, beta-blockers not only
affect heart rate, they also reduce blood pressure and alter cardiac
contractility, relaxation, systolic ejection time, and pulse-wave
reflection.
An interesting point is that for a given reduction in a heart rate,
the dyssynchrony between the forward and the reflected pulse wave
may not be the same for atenolol as for other beta-blockers. (3).
In addition to the potentially deleterious effect of beta-blockers,
as a group, on pulse-wave reflection for reasons unrelated to heart
rate reduction, other issues might be considered in assessing the
impact of beta-blockers, including, perhaps most importantly, the
magnitude of heart rate reduction achieved in the individual trials
or individual patients in the meta-analysis by Bangalore et al. (4),
which may determine the extent to which any deleterious effects of
beta-blockade might be obviated by heart rate slowing.
Therefore, the hypertension paradox observed with beta-
blockers (mainly atenolol) cannot be solely explained by pharma-
cologic heart rate slowing, and findings should not be extrapolated
to pharmacologic interventions aiming at pure heart rate reduction.
In other words, the way in which one slows the heart rate may be
important in determining the outcome of heart rate slowing. We
all are aware, however, of the limitations of observational datasets,
whether when suggesting benefit of a spontaneously “low” heart
rate or possible harm from pharmacologic heart rate reduction with
beta-blockers in hypertension. Fortunately, the hypothesis that
heart rate lowering is beneficial clinically is being put to test in 2
large-scale outcome randomized clinical trials.
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